Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatic acetyl-CoA content refers to the amount of the metabolite acetyl-coenzyme A present within liver cells. Acetyl-CoA is a central molecule in cellular metabolism, acting as a key intermediate that links carbohydrate, fat, and protein catabolism to energy production via the citric acid cycle[3]. In hepatocytes, it is generated primarily from glycolysis-derived pyruvate or from β-oxidation of fatty acids[1][2]. The fate of hepatic acetyl-CoA includes entry into the citric acid cycle for ATP generation or conversion into ketone bodies during fasting or carbohydrate restriction[2][3]. Regulation of hepatic acetyl-CoA levels involves multiple enzymes such as ACOT12 and ACOT8, which hydrolyze excess acetyl-CoA to acetate—this process helps recycle free Coenzyme A required for ongoing fatty acid oxidation under conditions like starvation or diabetes[1][5]. Abnormal accumulation or depletion of hepatic acetyl-CoA can disrupt normal metabolic fluxes. For example, impaired ketogenesis leads to increased diversion of acetyl-CoA into gluconeogenesis and oxidative pathways—a feature observed in NAFLD progression toward NASH (non-alcoholic steatohepatitis)[2]. Elevated hepatic acetyl-CoA also drives histone hyperacetylation in steatotic livers; this epigenetic change increases DNA damage risk and may initiate hepatocellular carcinoma development in chronic fatty liver disease states[4]. Blood acetate has been proposed as an emerging biomarker reflecting shifts in hepatic energy metabolism during stress conditions such as prolonged fasting or uncontrolled diabetes mellitus[5]. Note: "Hepatic acetyl-CoA content" describes a quantitative state rather than a discrete molecular target like an enzyme or receptor. It is not itself considered a therapeutic target but rather an important readout/parameter reflecting underlying metabolic processes. Therefore, it should not be classified alongside canonical drug targets such as receptors or enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic acetyl-CoA content.